PLoS ONE · 2015 · 51 citations · 25 references
MedicineOncologySurgerySurgical OncologyUltrasonographyUltrasoundAbdominal UltrasonographyAbdominal UltrasoundAblation TherapyHepatobiliary SurgeryLiver MetastasisUltrasound In OncologyColorectal Liver MetastasisCurative InterventionCurative TherapyHifu AblationHigh-intensity Focused UltrasoundLiver Metastases TreatmentLiver Tumor AblationUltrasound-guided Tumor Ablation
BACKGROUND: Surgery is the only curative treatment in patients with colorectal liver metastases (CLM), but only 10-20% of patients are eligible. High Intensity Focused Ultrasound (HIFU) technology is of proven value in several indications, notably prostate cancer. Its intra-operative use in patients with CLM has not previously been studied. Preclinical work suggested the safety and feasibility of a new HIFU device capable of ablating volumes of up to 2cm x 2cm in a few seconds. METHODS: We conducted a prospective, single-centre phase I-IIa trial. HIFU was delivered immediately before scheduled hepatectomy. To demonstrate the safety and efficacy of rapidly ablating liver parenchyma, ablations were performed on healthy tissue within the areas scheduled for resection. RESULTS: In total, 30 ablations were carried out in 15 patients. These ablations were all generated within 40 seconds and on average measured 27.5mm x 21.0mm. The phase I study (n = 6) showed that use of the HIFU device was feasible and safe and did not damage neighbouring tissue. The phase IIa study (n = 9) showed both that the area of ablation could be precisely targeted on a previously implanted metallic mark (used to represent a major anatomical structure) and that ablations could be undertaken deliberately to avoid such a mark. Ablations were achieved with a precision of 1-2 mm. CONCLUSION: HIFU was feasible, safe and effective in ablating areas of liver scheduled for resection. The next stage is a phase IIb study which will attempt ablation of small metastases with a 5 mm margin, again prior to planned resection. TRIAL REGISTRATION: ClinicalTrials.govNCT01489787.
25
Don C. Des Jarlais, Cynthia M. Lyles, Nicole Crepaz · American Journal of Public Health · 2004 · 2.6K citations · Full text
No surgical innovation without evaluation: the IDEAL recommendations
Peter McCulloch, Douglas G. Altman, David R. Flum et al. · The Lancet · 2009 · 1.8K citations
Bernard Nordlinger, Halfdan Sørbye, Bengt Glimelius et al. · The Lancet Oncology · 2013 · 1.3K citations
Two-Stage Hepatectomy: A Planned Strategy to Treat Irresectable Liver Tumors
René Adam, Alexis Laurent, Daniel Azoulay et al. · Annals of Surgery · 2000 · 796 citations